Biomarker & Intervention Discovery
Thyroid Cancer (Well-Differentiated)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionNot applicable — surgical resection is standard; papillary microcarcinoma (<1 cm, low-risk): active surveillance…
Best-intervention remissionTotal thyroidectomy + RAI for intermediate/high-risk: 90-95% disease-free survival at 10 years; active surveillance…
Gap sizeModerate — overtreatment of low-risk disease is the dominant problem (too many total thyroidectomies in low-risk…
Primary barrierpractice/framing
Full remission profile →
Remission & chronicity
Spontaneous remission
Not applicable — surgical resection is standard; papillary microcarcinoma (<1 cm, low-risk): active surveillance achieves 99.8%+ cancer-specific survival at 10 years without immediate surgery in Japanese cohorts
Best-intervention remission
Total thyroidectomy + RAI for intermediate/high-risk: 90-95% disease-free survival at 10 years; active surveillance for low-risk papillary microcarcinoma: non-inferior to surgery in multiple cohorts; lenvatinib + pembrolizumab for RAI-refractory: OS benefit (LEAP-011 ongoing); vemurafenib for BRAF V600E mutant: response in 38%
Gap size
Moderate — overtreatment of low-risk disease is the dominant problem (too many total thyroidectomies in low-risk disease)
Primary barrier
practice/framing
The Kuma Hospital and Cancer Institute Hospital experience in Japan showing non-inferiority of active surveillance for low-risk papillary microcarcinoma has not been widely adopted outside Japan; total thyroidectomy with radioiodine for all differentiated thyroid cancer remains common despite lack of benefit in low-risk disease
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Thyroid Cancer (Well-Differentiated)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."